Champions Oncology, Inc.
NASDAQ:CSBRBiotechnology
-$0.08 today
- Market cap
- $63.91M
- Beta
- 0.40
- P/E (TTM)
- -41.0
- EPS (TTM)
- -$0.16
Volume 0.00M
Average 0.01M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Champions Oncology, Inc.
NASDAQ:CSBR
Intrinsic Alpha fair value
Locked
Current Price
$4.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +104.3% | N/A0 analysts |
| Revenue | N/A | N/A | +5.1% | +7.5% (3yr)1 analysts |
| Net Income | N/A | N/A | +104.7% | N/A1 analysts |
| EBIT | N/A | N/A | +99.9% | N/A — |
Analysis
Recent growth has been strongest in Net Income at +104.7% over three years. Forward estimates point to Revenue at +7.5% (3yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Shattuck Labs, Inc. NASDAQ:STTK | $473.57M | $4.65 | Not rated | -10.9 | +128.36% |
Artiva Biotherapeutics, Inc. NASDAQ:ARTV | $198.22M | $4.01 | Not rated | -2.7 | -0.77% |
InflaRx N.V. NASDAQ:IFRX | $172.42M | $1.17 | Not rated | -2.7 | -9.45% |
Sutro Biopharma, Inc. NASDAQ:STRO | $162.83M | $9.82 | Not rated | -0.0 | +0.22% |
Oramed Pharmaceuticals Inc. NASDAQ:ORMP | $154.33M | $3.71 | Not rated | 1.4 | +66.81% |
Atara Biotherapeutics, Inc. NASDAQ:ATRA | $78.45M | $7.70 | Not rated | -14.7 | -51.71% |
Connect Biopharma Holdings Limited NASDAQ:CNTB | $42.65M | $0.68 | Not rated | -4.0 | -68.79% |
ImageneBio Inc NASDAQ:IMA | $39.39M | $3.47 | Not rated | -1.5 | -39.58% |
Kalaris Therapeutics Inc NASDAQ:KLRS | $37.49M | $1.58 | Not rated | -2.5 | -64.34% |
Continue the stock analysis
Jump to another research area for this company.